Introduction There is lack of comprehensive and up-to-date forecasted estimates for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), with inconsistencies in existing literature. The study estimated and forecasted incidence, prevalence, and treatment-eligible patient counts by line of therapy (LoT) for DLBCL and MCL in the US from 2023 to 2032. Methods Historical incidence rates for 2017-2022 (excluding 2020) from SEER-21 were used for projections. A validated joinpoint regression model forecasted age- and gender-specific incidence rates. A validated prevalence model incorporating incidence, survival, and cure likelihood estimated 5-, 10-, 15-, and 20-year prevalences. A new model estimated treatment-eligible DLBCL and MCL patients counts by LoT, integrating projected incidence, literature estimates on re‑entry patients, and SEER-Medicare treatment‑pattern data. Results From 2023 to 2032, DLBCL incidence is projected to rise by 7% (28,838 to 30,772) and MCL by 6% (3,377 to 3,589). The 5-, 10-, 15-, and 20-year prevalences are expected to increase by 11%, 16%, 18%, and 20% for DLBCL, and by 8%, 13%, 16%, and 19% for MCL. In DLBCL, treatment-eligible patients are estimated to increase by 7% in 1L (33,120 to 35,523) and by 8% in later lines (2L: 9,243 to 9,976; 3L: 4,466 to 4,821; 4L: 2,163 to 2,335). In MCL, treatment-eligible patients are expected to increase by 6% across all LoT (1L: 3,376 to 3,591; 2L: 1,220 to 1,297; 3L: 685 to 729; 4L: 379 to 405). Conclusion Projections indicate growing burdens of DLBCL and MCL in the US, informing healthcare planning and resource allocation.
Lin et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: